These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 39012070

  • 21. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, Hirata K.
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d'Onofrio F, d'Onofrio L, Rao R, Messina S, Di Clemente L, Ranieri A, Autunno M, Sette G, Colombo B, Carnevale A, Aguggia M, Tasillo M, Zoroddu F, Frediani F, Filippi M, Tomino C, Proietti S, Bonassi S, FRIEND-Study Group.
    J Headache Pain; 2023 Mar 23; 24(1):30. PubMed ID: 36949388
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, Olivier M, Campdelacreu J, Prat J, Camiña Muñiz J, Molina Martínez FJ, Mínguez-Olaondo A, Ruibal Salgado M, Santos Lasaosa S, Navarro Pérez MP, Morollón N, López Bravo A, Cano Sánchez LM, García-Sánchez SM, García-Ull J, Rubio-Flores L, Gonzalez-Martinez A, Quintas S, Echavarría Íñiguez A, Gil Luque S, Castro-Sánchez MV, Adell Ortega V, García Alhama J, Berrocal-Izquierdo N, Belvís R, Díaz-Insa S, Pozo-Rosich P, Huerta-Villanueva M.
    J Headache Pain; 2023 Jun 02; 24(1):63. PubMed ID: 37268904
    [Abstract] [Full Text] [Related]

  • 28. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
    Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.
    J Headache Pain; 2021 Oct 07; 22(1):120. PubMed ID: 34620085
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study.
    Braca S, Miele A, Stornaiuolo A, Cretella G, De Simone R, Russo CV.
    Neurol Sci; 2024 Apr 07; 45(4):1655-1660. PubMed ID: 38091211
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
    Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F, FRIEND-Study Group.
    J Headache Pain; 2022 Apr 09; 23(1):46. PubMed ID: 35397503
    [Abstract] [Full Text] [Related]

  • 34. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
    Yang CP, Zeng BY, Chang CM, Shih PH, Yang CC, Tseng PT, Wang SJ.
    Neurotherapeutics; 2021 Oct 09; 18(4):2639-2650. PubMed ID: 34580838
    [Abstract] [Full Text] [Related]

  • 35. Real-world effectiveness of erenumab in Japanese patients with migraine.
    Suzuki K, Suzuki S, Shiina T, Haruyama Y, Kobayashi S, Shioda M, Hirata K.
    Heliyon; 2024 Feb 29; 10(4):e26568. PubMed ID: 38420497
    [Abstract] [Full Text] [Related]

  • 36. Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study.
    Cresta E, Bellotti A, Rinaldi G, Corbelli I, Sarchielli P.
    CNS Neurosci Ther; 2024 Feb 29; 30(2):e14595. PubMed ID: 38332541
    [Abstract] [Full Text] [Related]

  • 37. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group.
    J Headache Pain; 2021 May 03; 22(1):35. PubMed ID: 33941080
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.